Belgian biotech Galapagos (Euronext & Nasdaq: GLPG) and Anglo-American biopharma Adaptimmune Therapeutics (Nasdaq: ADAP) have entered into a clinical collaboration agreement.
The deal includes an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head and neck cancer and potential future solid tumor indications, using Galapagos’ decentralized cell manufacturing platform.
Shares in Adaptimmune were 21% higher in pre-market trading on Friday following the announcement of the deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze